Efficacy, durability, and response predictors of low-dose interleukin-2 therapy for chronic graft-versus-host disease-Reference-Cited by-同舟云学术

Efficacy, durability, and response predictors of low-dose interleukin-2 therapy for chronic graft-versus-host disease

Published:2016-07-07 Issue:1 Volume:128 Page:130-137
ISSN:0006-4971
Container-title:Blood
language:en
Short-container-title:

Author:

Koreth John¹,Kim Haesook T.²,Jones Kyle T.¹,Lange Paulina B.¹,Reynolds Carol G.¹,Chammas Marie J.¹,Dusenbury Katherine¹,Whangbo Jennifer¹,Nikiforow Sarah¹,Alyea Edwin P.¹,Armand Philippe¹,Cutler Corey S.¹,Ho Vincent T.¹,Chen Yi-Bin³,Avigan David⁴,Blazar Bruce R.⁵,Antin Joseph H.¹,Ritz Jerome¹,Soiffer Robert J.¹

Affiliation:

1. Division of Hematologic Malignancies, Dana-Farber Cancer Institute and Harvard Medical School, Boston, MA;

2. Department of Biostatistics & Computational Biology, Dana-Farber Cancer Institute and Harvard School of Public Health, Boston, MA;

3. Hematology/Oncology Division, Massachusetts General Hospital and Harvard Medical School, Boston, MA;

4. Hematology/Oncology, Beth Israel Deaconess Medical Center and Harvard Medical School, Boston, MA; and

5. University of Minnesota Masonic Cancer Center and Division of Blood and Marrow Transplantation, Department of Pediatrics, Minneapolis, MN

Abstract

Key Points Low-dose IL-2 is efficacious in steroid-refractory cGVHD, with objective responses in >50% of patients, and durable disease control. IL-2 initiation earlier after cGVHD onset, prior to severe impairment of Treg:Tcon ratios, improves likelihood of clinical response.

Publisher

American Society of Hematology

Subject

Cell Biology,Hematology,Immunology,Biochemistry

Link

http://ashpublications.org/blood/article-pdf/128/1/130/1395501/130.pdf

Reference41 articles.

1. Patient-reported quality of life is associated with severity of chronic graft-versus-host disease as measured by NIH criteria: report on baseline data from the Chronic GVHD Consortium.;Pidala;Blood,2011

2. Current issues in chronic graft-versus-host disease.;Socié;Blood,2014

3. How we treat chronic graft-versus-host disease.;Flowers;Blood,2015

4. Naturally-occurring CD4+CD25+ immunoregulatory T cells: central players in the arena of peripheral tolerance.;Piccirillo;Semin Immunol,2004

5. Development and function of CD25+CD4+ regulatory T cells.;Fehérvari;Curr Opin Immunol,2004

Cited by 174 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. The role of interleukin-2 in graft-versus-host disease pathogenesis, prevention and therapy;Cytokine;2024-11

2. Low-dose interleukin-2 in birch pollen allergy: a phase-2 randomized double-blind placebo-controlled trial;2024-09-04

3. Innovations in Childhood Interstitial and Diffuse Lung Disease;Clinics in Chest Medicine;2024-09

4. The Application of Umbilical Cord Blood-derived Platelet Gel for Skin Ulcers Associated With Chronic Graft-Versus-Host Disease in Pediatrics: A Randomized Trial;Transplantation and Cellular Therapy;2024-07

5. The impact of regulatory T cells on the graft-versus-leukemia effect;Frontiers in Immunology;2024-04-22